Berkshire Hathaway stock: OxyChem deal closes as investors size up the Abel era

Berkshire Hathaway stock: OxyChem deal closes as investors size up the Abel era

NEW YORK, Jan 4, 2026, 14:01 ET — Market closed

Berkshire Hathaway said on Friday it completed its acquisition of Occidental Petroleum’s chemicals business OxyChem, a $9.7 billion all-cash deal that adds a major plastics and industrial chemicals producer to the conglomerate. Business Wire

The timing matters. Berkshire is entering 2026 with investors focused on how the company puts money to work after a long stretch of sitting on cash and trimming some big equity positions, even as markets remain richly valued.

It also lands as Berkshire shifts from a Warren Buffett-led story to one where capital allocation and succession are no longer theoretical. “It’s hard to imagine that there will be the same cult following,” said Brian Jacobsen, chief economic strategist at Annex Wealth Management. Reuters

Berkshire’s Class B shares closed on Friday down 1.15% at $496.85, lagging a broader market that ended modestly higher on the first trading day of 2026. Nasdaq

OxyChem’s purchase price is subject to post-closing adjustments, meaning the final bill can move based on customary balance-sheet true-ups. Occidental said an affiliate retained certain legacy tort claims and environmental liabilities tied mainly to historical operations outside the footprint of the facilities that were sold. Oxy

The deal had been announced in October as part of Occidental’s effort to cut debt after a string of big acquisitions, and it expands Berkshire’s chemical footprint beyond Lubrizol. Reuters

Even so, the $9.7 billion outlay is small next to Berkshire’s war chest, putting a spotlight back on whether the company leans into more acquisitions, steps up buybacks, or stays patient if prices don’t come down.

But there are risks. Chemicals are cyclical, and profits can swing with construction and industrial demand; investors will also watch whether the transition period brings more conservatism than markets are willing to price in.

With U.S. trading set to resume on Monday, investors will be looking for any fresh signals on capital deployment, and whether Berkshire’s next results provide a clearer read on how management wants to balance cash, buybacks and deals.

The next fixed date on the calendar is Berkshire’s shareholder meeting on May 2, which will be the first annual gathering of the new era and a key test of how the company communicates after Buffett’s handoff. Berkshirehathaway

Stock Market Today

  • AstraZeneca Stock Seen 7.6% Undervalued Amid Strong Pipeline and Recent Gains
    January 28, 2026, 5:12 AM EST. AstraZeneca (LSE:AZN) shares have gained 10.51% over three months, with a one-year total shareholder return of 26.95%, highlighting rising investor interest. Trading at £138.80 and estimated 7.6% undervalued against a £150.26 fair value, the company's robust late-stage pipeline - focused on oncology, rare diseases, and cardiovascular therapies - underpins growth forecasts. Analysts expect over $10 billion in peak risk-adjusted revenues from new products, supporting future earnings expansion. However, high valuation with a 31.6x price-to-earnings ratio versus European pharma average of 25.9x raises caution, alongside risks like patent expirations, biosimilar competition, and government price controls. Investors can explore personalized valuation models to assess AstraZeneca's outlook amid evolving market dynamics.
Freshworks stock drops 5% to start 2026 — what matters before Monday’s open (FRSH)
Previous Story

Freshworks stock drops 5% to start 2026 — what matters before Monday’s open (FRSH)

Consumer Cyclical Stocks wobble into Monday as Tesla drags XLY and jobs report looms
Next Story

Consumer Cyclical Stocks wobble into Monday as Tesla drags XLY and jobs report looms

Go toTop